Loading market dashboard
Beta Bionics, Inc.
BBNXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws.
Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
SAN DIEGO--(BUSINESS WIRE)---- $bbnx #BBNX--Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.What if I purchased Beta Bionics securities?If you purchased Beta Bionics securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.Or for more informat.
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to De
SAN DIEGO, June 2, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
San Diego, California--(Newsfile Corp. - June 2, 2026) - Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
IRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is now publicly available at betabionics.com/hcp/real-world-data.
SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BetaBionicsInc--Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.On January 8, 2026, Beta Bioni.
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (FDA). The updated Mint commercialization timeline expectation is based on the FDA's initial responses to the company's Mint alternate controller enabled (ACE) insulin pump 510(k) application, and the progress the company has made in scaling its Mint manufacturing processes. The company expects manufacturing capacity to meet anticipated demand at launch.
Beta Bionics NASDAQ: BBNX Chief Financial Officer Stephen Feider said the company's first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company's iLet insulin pump platform.
Beta Bionics, Inc. (BBNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Leading contributors in the First Eagle Small Cap Opportunity Fund this quarter included Ultra Clean Holdings, Oil States International, Lincoln Educational Services, Advanced Energy and FormFactor. Oil States International shares rallied on very strong bookings during the quarter and improved operator-powered solutions and services inside the wellbore. The leading detractors in the quarter were Vital Farms, Alphatec Holdings, Beta Bionics, SI-BONE. and Herc Holdings.
IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 pm Eastern Time (11:20 am Pacific Time).
Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.52 per share a year ago.
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026.
Beta Bionics, Inc. (BBNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Beta Bionics, Inc. (“Beta Bionics" or the "Company") (NASDAQ: BBNX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results after the financial markets close on Tuesday, April 21, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's first quarter 2026 performance.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 28, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses Beta Bionics Stock or Options To Contact Him Directly At 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 20, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 17, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 12, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX).
Beta Bionics (NASDAQ: BBNX) executives used a conference presentation to outline the company's strategy in insulin delivery, emphasizing automation, pharmacy reimbursement, and an expanding commercial footprint as key pillars of its growth plan. Positioning iLet around "automation-forward" insulin delivery Chief Financial Officer Stephen Feider described Beta Bionics' iLet insulin pump as differentiated primarily by its approach
